NEO - NeoGenomics Inc Stock Price, Fair Value and News

14.81USD-0.18 (-1.20%)Delayed

Market Summary

USD14.81-0.18

Delayed

-1.20%

NEO Alerts

Losses in recent quarter

NEO Stock Price

View Fullscreen

NEO RSI Chart

NEO Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-22.45

Price/Sales (Trailing)

3.1

EV/EBITDA

-47.36

Price/Free Cashflow

-47.78

NEO Price/Sales (Trailing)

NEO Profitability

EBT Margin

-14.91%

Return on Equity

-9.12%

Return on Assets

-5.14%

Free Cashflow Yield

-2.09%

NEO Fundamentals

NEO Revenue

Revenue (TTM)

610.7M

Rev. Growth (Yr)

13.86%

Rev. Growth (Qtr)

0.44%

NEO Earnings

Earnings (TTM)

-84.2M

Earnings Growth (Yr)

12.13%

Earnings Growth (Qtr)

-88.89%

Breaking Down NEO Revenue

Last 7 days

-6.1%

Last 30 days

8.3%

Last 90 days

3.1%

Trailing 12 Months

-17.9%

How does NEO drawdown profile look like?

NEO Financial Health

Current Ratio

7.48

Debt/Equity

0.58

Debt/Cashflow

-0.03

NEO Investor Care

Shares Dilution (1Y)

0.10%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	610.7M	0	0	0
2023	529.8M	551.6M	574.8M	591.6M
2022	486.0M	489.3M	496.8M	509.7M
2021	454.0M	488.7M	484.6M	484.3M
2020	419.3M	404.5M	425.3M	444.4M
2019	308.9M	342.9M	378.4M	408.8M
2018	246.2M	251.7M	261.7M	276.7M
2017	241.8M	240.9M	239.3M	240.3M
2016	136.5M	175.2M	210.9M	244.1M
2015	91.9M	95.6M	97.5M	99.8M
2014	69.0M	74.1M	80.4M	87.1M
2013	60.4M	60.4M	63.0M	66.5M
2012	49.8M	55.0M	57.9M	59.9M
2011	36.6M	38.9M	41.2M	43.5M
2010	0	0	0	34.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NeoGenomics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	aunan greg d	sold (taxes)	-	-	-937	chief accounting officer
May 01, 2024	olivo alicia c	sold (taxes)	-	-	-652	general counsel
Mar 04, 2024	tetrault lynn a.	sold	-97,578	15.9651	-6,112	-
Feb 15, 2024	olivo alicia c	sold	-38,712	14.9644	-2,587	general counsel
Jan 01, 2024	harris melody	sold (taxes)	-	-	-7,123	president, enterprise ops
Dec 07, 2023	sherman jeffrey scott	sold (taxes)	-	-	-8,147	chief financial officer
Dec 01, 2023	stone warren	sold (taxes)	-	-	-5,431	president, clinical services
Nov 17, 2023	olivo alicia c	sold	-49,082	18.39	-2,669	general counsel
Sep 30, 2023	olivo alicia c	sold (taxes)	-	-	-14.00	general counsel
Sep 01, 2023	olivo alicia c	sold (taxes)	-	-	-1,666	general counsel

Which funds bought or sold NEO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Pineridge Advisors LLC	reduced	-91.29	-4,932	456	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.29	-173,764	2,003,500	-%
May 16, 2024	JANE STREET GROUP, LLC	added	49.14	1,304,200	4,209,190	-%
May 16, 2024	COMERICA BANK	reduced	-8.98	-120,600	921,554	-%
May 15, 2024	Bellevue Group AG	new	-	14,871,500	14,871,500	0.23%
May 15, 2024	Point72 Asset Management, L.P.	new	-	34,545,500	34,545,500	0.08%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	sold off	-100	-897,197	-	-%
May 15, 2024	Greenhouse Funds LLLP	added	1.46	-997,757	69,110,700	4.17%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-95.87	-642,776	26,849	-%
May 15, 2024	Gotham Asset Management, LLC	sold off	-100	-206,538	-	-%

Are Funds Buying or Selling NEO?

Are funds buying NEO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NEO

No. of Funds

NEO Alerts

Losses in recent quarter

Unveiling NeoGenomics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	5.0%	6,382,515	SC 13G
Feb 13, 2024	vanguard group inc	11.12%	14,169,665	SC 13G/A
Feb 09, 2024	brown advisory inc	0.1%	9,536,307	SC 13G/A
Jan 22, 2024	blackrock inc.	15.7%	19,980,993	SC 13G/A
Feb 10, 2023	artisan partners limited partnership	0.0%	10	SC 13G/A
Feb 09, 2023	brown advisory inc	5%	6,337,008	SC 13G
Feb 09, 2023	vanguard group inc	10.83%	13,674,745	SC 13G/A
Feb 06, 2023	wellington management group llp	0.00%	0	SC 13G/A
Jan 23, 2023	blackrock inc.	17.4%	21,932,623	SC 13G/A
Feb 04, 2022	artisan partners limited partnership	6.3%	7,732,355	SC 13G

Recent SEC filings of NeoGenomics Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 15, 2024	144	Notice of Insider Sale Intent
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading

Peers (Alternatives to NeoGenomics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

NeoGenomics Inc News

Latest updates

NeoGenomics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	0.4%	156,240,000	155,552,000	151,954,000	146,917,000	137,220,000	138,705,000	128,782,000	125,072,000	117,169,000	125,732,000	121,340,000	121,724,000	115,533,000	125,997,000	125,444,000	86,977,000	106,030,000	106,868,000	104,672,000	101,713,000	95,577,000
Gross Profit	-3.1%	65,469,000	67,588,000	62,311,000	59,891,000	54,814,000	56,825,000	48,893,000	43,946,000	38,232,000	45,257,000	47,239,000	52,990,000	41,574,000	57,453,000	54,065,000	28,006,000	46,369,000	49,923,000	50,832,000	48,966,000	47,115,000
Operating Expenses	11.5%	96,036,000	86,162,000	86,506,000	89,785,000	89,887,000	83,208,000	88,403,000	83,648,000	90,260,000	86,824,000	86,952,000	75,357,000	56,681,000	51,914,000	49,396,000	46,913,000	51,662,000	47,602,000	47,173,000	44,488,000	44,567,000
S&GA Expenses	11.9%	20,221,000	18,072,000	17,610,000	18,901,000	16,259,000	17,142,000	16,809,000	17,071,000	16,299,000	15,917,000	15,704,000	17,224,000	13,749,000	13,105,000	11,304,000	10,195,000	13,258,000	12,302,000	11,508,000	12,324,000	11,216,000
R&D Expenses	6.9%	7,620,000	7,127,000	5,285,000	7,502,000	7,395,000	6,675,000	7,312,000	8,626,000	7,713,000	8,513,000	7,409,000	3,495,000	2,456,000	2,100,000	1,964,000	2,105,000	2,060,000	2,080,000	2,611,000	2,587,000	1,209,000
EBITDA Margin	16.0%	-0.07	-0.09	-0.12	-0.15	-0.18	-0.23	-0.28	-0.25	-0.02	0.05	0.15	0.20	-	-	-	-	-	-	-	-	-
Interest Expenses	-86.1%	1,685,000	12,126,000	-2,840,000	-2,524,000	1,757,000	6,516,000	139,000	926,000	-1,301,000	4,845,000	1,296,000	902,000	1,177,000	2,194,000	2,458,000	1,548,000	819,000	380,000	203,000	1,304,000	1,826,000
Income Taxes	35.4%	-620,000	-960,000	-2,935,000	-2,309,000	-2,925,000	-2,837,000	-2,772,000	-5,730,000	-3,753,000	-2,445,000	-2,822,000	-2,437,000	976,000	-7,850,000	-335,000	-11,132,000	1,089,000	-3,861,000	1,348,000	175,000	-2,023,000
Earnings Before Taxes	-81.1%	-27,681,000	-15,286,000	-21,451,000	-26,640,000	-33,720,000	-25,524,000	-39,624,000	-41,033,000	-53,161,000	-44,203,500	-23,170,000	73,436,000	-21,138,000	7,567,000	2,222,000	-17,956,000	-5,889,000	2,435,000	3,491,000	2,166,000	-4,447,000
EBT Margin	9.1%	-0.15	-0.16	-0.19	-0.23	-0.26	-0.31	-0.36	-0.33	-0.10	-0.03	0.08	0.13	-	-	-	-	-	-	-	-	-
Net Income	-88.9%	-27,061,000	-14,326,000	-18,516,000	-24,331,000	-30,795,000	-22,687,000	-36,852,000	-35,303,000	-49,408,000	-41,758,500	-20,348,000	75,873,000	-22,114,000	15,417,000	2,557,000	-6,824,000	-6,978,000	6,296,000	2,143,000	1,991,000	-2,424,000
Net Income Margin	7.2%	-0.14	-0.15	-0.17	-0.21	-0.24	-0.28	-0.33	-0.30	-0.07	-0.02	0.10	0.15	-	-	-	-	-	-	-	-	-
Free Cashflow	-393.7%	-31,500,000	10,727,000	-9,771,000	-9,042,000	-22,619,000	-8,219,000	-24,116,000	-27,290,000	-37,259,000	-31,763,000	-22,744,000	-22,737,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.4%	1,640	1,681	1,678	1,695	1,709	1,740	1,756	1,792	1,830	1,870	1,906	1,896	1,494	1,227	959	945	732	710	711	697	533
Current Assets	-3.8%	574	597	587	585	585	605	603	622	651	682	710	722	943	449	422	419	215	291	292	276	116
Cash Equivalents	-3.1%	332	342	306	289	276	263	266	284	306	317	341	369	612	251	233	295	86.00	173	179	167	13.00
Inventory	-15.9%	20.00	24.00	24.00	25.00	24.00	24.00	24.00	22.00	24.00	23.00	22.00	21.00	21.00	30.00	21.00	22.00	20.00	14.00	13.00	9.00	10.00
Net PPE	-4.5%	88.00	92.00	95.00	100	103	102	107	111	109	109	107	112	94.00	86.00	85.00	84.00	83.00	64.00	62.00	59.00	61.00
Goodwill	0%	523	523	523	523	523	523	523	527	527	527	526	267	45.00	211	211	211	211	199	199	196	196
Liabilities	-3.1%	717	740	731	739	735	742	743	749	755	762	769	748	651	294	293	291	227	202	214	207	209
Current Liabilities	-20.3%	77.00	96.00	93.00	95.00	87.00	90.00	85.00	83.00	82.00	87.00	93.00	99.00	68.00	73.00	65.00	62.00	68.00	64.00	69.00	59.00	73.00
Long Term Debt	0.1%	539	538	537	537	536	535	535	534	533	532	532	531	530	168	166	165	-	-	-	-	-
LT Debt, Non Current	0.1%	539	538	537	537	536	535	535	534	533	532	532	531	530	168	166	165	-	-	-	-	-
Shareholder's Equity	-1.9%	923	942	947	956	974	998	1,013	1,044	1,075	1,108	1,137	1,148	844	694	666	654	505	507	497	490	324
Retained Earnings	-11.0%	-274	-247	-232	-214	-189	-159	-136	-99.55	-64.24	-14.84	27.00	47.00	-28.60	-7.18	-22.60	-25.16	-18.33	-11.36	-17.65	-51.69	-53.68
Additional Paid-In Capital	0.7%	1,199	1,190	1,182	1,173	1,167	1,161	1,154	1,147	1,142	1,124	1,111	1,101	872	701	689	679	526	520	517	543	379
Accumulated Depreciation	5.9%	168	158	155	147	139	132	125	123	116	110	112	105	99.00	93.00	86.00	80.00	74.00	69.00	64.00	59.00	55.00
Shares Outstanding	0.1%	127	127	127	127	125	127	124	124	124	120	119	117	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,400	-	-	-	755	-	-	-	4,100	-	-	-	2,800	-	-	-	1,900	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-245.7%	-25,915	17,784	-5,497	-1,548	-12,692	-3,685	-16,272	-16,996	-29,040	-19,776	-7,767	-1,390	2,210	5,985	526	1,882	-6,933	3,359	18,634	-4,721	6,097
Share Based Compensation	11.2%	7,774	6,990	7,180	5,705	4,758	4,663	4,280	3,626	12,103	10,062	5,237	4,506	2,653	2,676	2,715	2,635	2,186	2,273	3,275	2,313	2,139
Cashflow From Investing	-15.5%	14,525	17,195	20,821	14,949	23,742	-1,063	-4,198	-6,274	12,052	-9,583	-14,686	-453,410	-154,688	-28,854	-70,716	-18,163	-41,708	-6,076	-7,316	-3,042	-3,196
Cashflow From Financing	-35.7%	816	1,270	1,841	64.00	1,379	1,802	2,959	1,011	6,057	2,460	-6,720	204,610	524,935	8,265	4,115	222,600	617	-3,158	137	162,004	483

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NEO Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total net revenue	$ 156,240	$ 137,220
COST OF REVENUE	90,771	82,406
GROSS PROFIT	65,469	54,814
Operating expenses:
General and administrative	65,797	61,549
Research and development	7,620	7,395
Sales and marketing	20,221	16,259
Restructuring charges	2,398	4,684
Total operating expenses	96,036	89,887
LOSS FROM OPERATIONS	(30,567)	(35,073)
Interest income	(4,834)	(3,224)
Interest expense	1,685	1,757
Other expense (income), net	263	114
Loss before taxes	(27,681)	(33,720)
Income tax benefit	(620)	(2,925)
NET LOSS	$ (27,061)	$ (30,795)
NET LOSS PER SHARE
Basic (in dollars per share)	$ (0.21)	$ (0.25)
Diluted (in dollars per share)	$ (0.21)	$ (0.25)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)	126,111	125,026
Diluted (in shares)	126,111	125,026
Clinical Services
Total net revenue	$ 134,535	$ 114,869
COST OF REVENUE	76,844	67,292
GROSS PROFIT	57,691	47,577
Advanced Diagnostics
Total net revenue	21,705	22,351
COST OF REVENUE	13,927	15,114
GROSS PROFIT	$ 7,778	$ 7,237

NEO Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 331,914	$ 342,488
Marketable securities, at fair value	52,916	72,715
Accounts receivable, net	140,279	131,227
Inventories	20,320	24,156
Prepaid assets	19,155	17,987
Other current assets	9,312	8,239
Total current assets	573,896	596,812
Property and equipment (net of accumulated depreciation of $167,584 and $158,211, respectively)	87,865	92,012
Operating lease right-of-use assets	86,578	91,769
Intangible assets, net	364,764	373,128
Goodwill	522,766	522,766
Other assets	4,470	4,742
Total non-current assets	1,066,443	1,084,417
Total assets	1,640,339	1,681,229
Current liabilities
Accounts payable	18,336	20,334
Accrued compensation	34,609	53,161
Accrued expenses and other liabilities	18,134	15,069
Current portion of operating lease liabilities	4,487	5,610
Contract liabilities	1,144	2,130
Total current liabilities	76,710	96,304
Long-term liabilities
Convertible senior notes, net	538,923	538,198
Operating lease liabilities	64,773	67,871
Deferred income tax liabilities, net	23,490	24,285
Other long-term liabilities	13,033	13,034
Total long-term liabilities	640,219	643,388
Total liabilities	716,929	739,692
Commitments and contingencies (Note 11)
Stockholders’ equity
Common stock, $0.001 par value, (250,000,000 shares authorized; 127,434,786 and 127,369,142 shares issued and outstanding, respectively)	127	127
Additional paid-in capital	1,198,729	1,190,139
Accumulated other comprehensive loss	(1,330)	(1,674)
Accumulated deficit	(274,116)	(247,055)
Total stockholders’ equity	923,410	941,537
Total liabilities and stockholders’ equity	$ 1,640,339	$ 1,681,229

About NeoGenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

CEO	Mr. Christopher Michael Smith BSc
WEBSITE	neogenomics.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	2100

NeoGenomics Inc Frequently Asked Questions

What is the ticker symbol for NeoGenomics Inc? What does NEO stand for in stocks?

NEO is the stock ticker symbol of NeoGenomics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeoGenomics Inc (NEO)?

As of Fri May 17 2024, market cap of NeoGenomics Inc is 1.89 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NEO stock?

You can check NEO's fair value in chart for subscribers.

What is the fair value of NEO stock?

You can check NEO's fair value in chart for subscribers. The fair value of NeoGenomics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NeoGenomics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NEO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NeoGenomics Inc a good stock to buy?

The fair value guage provides a quick view whether NEO is over valued or under valued. Whether NeoGenomics Inc is cheap or expensive depends on the assumptions which impact NeoGenomics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NEO.

What is NeoGenomics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NEO's PE ratio (Price to Earnings) is -22.45 and Price to Sales (PS) ratio is 3.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NEO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on NeoGenomics Inc's stock?

In the past 10 years, NeoGenomics Inc has provided 0.155 (multiply by 100 for percentage) rate of return.